Zealand Pharma Advances ZP2929 Into Phase I Development for the Treatment of Type 2 Diabetes and/or Obesity  
9/13/2012 9:33:36 AM

COPENHAGEN, Denmark, Sept. 13, 2012 (GLOBE NEWSWIRE) -- Zealand Pharma A/S (Copenhagen:ZEAL), a Danish biotechnology company dedicated to the discovery and development of innovative peptide drugs, announces that the first participant has been dosed in the first Phase I clinical study of ZP2929.